Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Taiko Pharmaceutical Co., Ltd. ( (JP:4574) ) just unveiled an update.
Taiko Pharmaceutical Co., Ltd. announced its consolidated financial results for the fiscal year ended December 31, 2024. The company reported a net sales increase of 2.8% compared to the previous year, with a significant turnaround in profitability, achieving a profit of 898 million yen after a loss of 3,611 million yen in 2023. This positive performance reflects improved operational efficiency and a stronger market presence, bolstering its equity-to-asset ratio to 61.7% from 51.0% in the prior year.
More about Taiko Pharmaceutical Co., Ltd.
Taiko Pharmaceutical Co., Ltd. operates in the pharmaceutical industry and is listed on the Tokyo Stock Exchange. The company is known for its products like Seirogan, which is a well-known herbal medicine in Japan, and focuses on delivering healthcare products that cater to both domestic and international markets.
YTD Price Performance: 0.30%
Average Trading Volume: 112,754
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen16.63B
See more insights into 4574 stock on TipRanks’ Stock Analysis page.